2. Search Result
Search Result
Results for "

radionuclides therapy

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

2

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139564
    DOTA Zoledronate

    		Others Cancer
    DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases .
    DOTA Zoledronate
  • HY-164589
    NOPO

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NOPO is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    NOPO
  • HY-164653
    DOTAEt

    		Others Cancer
    DOTAEt is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTAEt
  • HY-164590
    BCN-NODAGA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    BCN-NODAGA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    BCN-NODAGA
  • HY-164599
    TA-DOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    TA-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    TA-DOTA
  • HY-P10730
    DOTA-Lanreotide

    		Others Cancer
    DOTA-Lanreotide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-Lanreotide
  • HY-P10731
    DOTA-NAPamide

    		Others Cancer
    DOTA-NAPamide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-NAPamide
  • HY-164657
    Polyamidoamine

    PAMAM

    		 Others Cancer
    Polyamidoamine (PAMAM) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    Polyamidoamine
  • HY-164592
    DTPA-tetra(tBu)ester

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DTPA-tetra(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DTPA-tetra(tBu)ester
  • HY-164594
    TA-DOTA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    TA-DOTA-GA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    TA-DOTA-GA
  • HY-P10732
    DOTA-cyclo(RGDfK)

    		Others Cancer
    DOTA-cyclo(RGDfK) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-cyclo(RGDfK)
  • HY-W999782
    Propargyl-DOTA-tris(tBu)ester

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Propargyl-DOTA-tris(tBu)ester is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    Propargyl-DOTA-tris(tBu)ester
  • HY-P10729
    DOTA-Bombesin (1-14)

    		Others Cancer
    DOTA-Bombesin (1-14) is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-Bombesin (1-14)
  • HY-164603
    3p-C-NOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-NOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-NOTA
  • HY-164604
    3p-C-DEPA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-DEPA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-DEPA
  • HY-164606
    3p-C-NETA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-NETA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-NETA
  • HY-164596
    THP(Bz3)-Glu

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    THP(Bz3)-Glu is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    THP(Bz3)-Glu
  • HY-164654
    DOTA-PEG10-azide

    		Others Cancer
    DOTA-PEG10-azide is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-PEG10-azide
  • HY-W999766
    Propargyl-NOTA(tBu)2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Propargyl-NOTA(tBu)2 is a bifunctional chelating ligand that can bind to radionuclides to prepare radionuclide conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    Propargyl-NOTA(tBu)2
  • HY-W586475
    Fluorescein-triazole-PEG5-DOTA

    		Others Cancer
    Fluorescein-triazole-PEG5-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    Fluorescein-triazole-PEG5-DOTA
  • HY-164591
    THP(Bz)3-NH2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    THP(Bz)3-NH2 is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    THP(Bz)3-NH2
  • HY-164601
    3p-C-DE4TA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-DE4TA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-DE4TA
  • HY-164602
    3p-C-NE3TA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    3p-C-NE3TA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    3p-C-NE3TA
  • HY-164593
    NH-CH2-CH2-DOTAM

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH-CH2-CH2-DOTAM is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    NH-CH2-CH2-DOTAM
  • HY-164656
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE

    		Others Cancer
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy .
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE
  • HY-164588
    NH2-PEG4-NODA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2-PEG4-NODA-GA is a NODA-type metal chelator that can bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NH2-PEG4-NODA-GA
  • HY-W873634
    TRAP

    TRAP-Pr

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    TRAP-Pr is a radionuclide conjugate (RDC) that can bind to the radionuclide [68]Ga. RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. TRAP-Pr can be further functionalized with acetone and used in click chemistry CuAAC reactions to conjugate other labeled molecules.
    TRAP
  • HY-132989
    Mal-Deferoxamine

    		Reactive Oxygen Species Apoptosis Autophagy HIF/HIF Prolyl-Hydroxylase Akt Radionuclide-Drug Conjugates (RDCs) Cancer
    Mal-Deferoxamine is a maleamide (Mal)-containing Deferoxamine (HY-B1625). Mal selectively covalently binds to sulfur groups to produce a linking reaction. Mal-Deferoxamine can be combined with radionuclides to synthesize radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. .
    Mal-Deferoxamine
  • HY-W011118
    DTPA anhydride

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DTPA anhydride is a bifunctional chelator whose anhydride can react with amino groups in proteins (such as lysine residues) to form stable amide bonds. DTPA anhydride can also bind to radionuclides to synthesize radionuclide-labeled drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    DTPA anhydride
  • HY-147057
    FAP-2286
    1 Publications Verification

    		 FAP Cancer
    FAP-2286 is a potent and selective FAP-binding peptide coupled to a radionuclide chelator with a mean IC50 value of 2.7 nM for binding to FAP. FAP-2286 can chelate radionuclides for imaging or therapeutic applications and has a strong effect on FAP-positive tumors. FAP-2286 can be used for FAP-positive tumor research .
    FAP-2286
  • HY-106244
    DOTATATE

    		Radionuclide-Drug Conjugates (RDCs) Others Cancer
    DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) .
    DOTATATE
  • HY-106244A
    DOTATATE acetate

    		Radionuclide-Drug Conjugates (RDCs) Others Cancer
    DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) .
    DOTATATE acetate
  • HY-W755033
    NH2-PEG4-DOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2-PEG4-DOTA is a bifunctional, DOTA-type metal chelator. NH2-PEG4-DOTA can be conjugated with Dextran for quantitative analysis in the presence of a highly luminescent complex. NH2-PEG4-DOTA can also bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NH2-PEG4-DOTA
  • HY-158125
    PSMA binder-2

    		PSMA Cancer
    PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
    PSMA binder-2
  • HY-158123
    PSMA binder-1

    		PSMA Cancer
    PSMA binder-1 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or it can be labeled with 225Ac (to obtain Actinium-225-PSMA-Trillium (BAY 3563254)), which has a radioactive killing effect; it can be used as a Macropa chelator for targeted radionuclide therapy (TRT) , has a strong inhibitory effect on metastatic castration-resistant prostate cancer (mCRPC) .
    PSMA binder-1
  • HY-158122
    Lys(CO-C3-p-I-Ph)-O-tBu

    		DNA-PK Cancer
    Lys(CO-C3-p-I-Ph)-O-tBu is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules. Lys(CO-C3-p-I-Ph)-O-tBu can increase the residence time of PSMA ligand in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-O-tBu also reduces salivary gland absorption, possibly extending the half-life of the active compound. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
    Lys(CO-C3-p-I-Ph)-O-tBu
  • HY-158118
    Lys(CO-C3-p-I-Ph)-OMe

    		DNA-PK Cancer
    Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
    Lys(CO-C3-p-I-Ph)-OMe

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: